Form 4: Indivior Pharmaceuticals Director Trades Common Stock

Director Juliet Thompson reported transactions involving Indivior Pharmaceuticals common stock, including the acquisition of Restricted Stock Units and the sale of shares to cover tax withholding.

Summary

• Director Juliet Thompson engaged in transactions related to Indivior Pharmaceuticals, Inc. (INDV) common stock.
• On May 12, 2026, 1,117 shares were disposed of at a price of $38.28 to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Thompson beneficially owns 6,455 shares directly.
• On May 13, 2026, Thompson acquired 6,518 RSUs, with each RSU representing a contingent right to one share of common stock.
• These RSUs vest on the day before the annual stockholders' meeting following the grant date, contingent on continued service.
• After the RSU grant, Thompson's direct beneficial ownership increased to 12,973 shares.
• Additionally, 5,775 shares are held indirectly by spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions related to compensation and tax obligations rather than significant strategic shifts or performance indicators.

Positives

• Director Juliet Thompson received a grant of 6,518 Restricted Stock Units (RSUs), indicating continued equity-based compensation and alignment with the company's performance.
• The vesting of RSUs is tied to continued service, incentivizing long-term commitment from the director.

Negatives

• 1,117 shares were disposed of to cover tax withholding obligations, representing a reduction in directly held shares.

Future Outlook

The Restricted Stock Units granted on May 13, 2026, are set to vest on the day immediately preceding the annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. These transactions, particularly RSU grants and tax withholdings, are common compensation and liquidity management practices within the pharmaceutical industry.

Stakeholder Impact

• Shareholders: Increased transparency into director's equity holdings and compensation structure.
• Employees: The RSU grant reflects a standard employee incentive program, potentially impacting morale and retention.
• Management: The transactions are routine and do not indicate any immediate strategic shifts impacting management's operational focus.

Next Steps

• Vesting of Restricted Stock Units on the day before the annual stockholders' meeting following the grant date, subject to continued service.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Transaction, Restricted Stock Units, Indivior Pharmaceuticals, Director Compensation, Beneficial Ownership